Latest news with #MerilLifeSciences
Time of India
04-07-2025
- Health
- Time of India
Latur grandmom gets Rs 19 lakh gift from KEM Hospital in Mumbai: A clip for her leaky heart valve
Mumbai: For a 66-year-old grandmother from Latur who was breathing with difficulty for almost six months, doctors at the civic-run KEM Hospital had a surprise gift: a Rs 19-lakh new device to fix the leaking mitral valve causing her symptoms. The mitral valve is one of the four that regulates the flow of blood through the heart. When it becomes diseased, the patient suffers from shortness of breath, fatigue, dry cough, and fainting spells, among other symptoms. Worse, the patient could develop heart failure or even a stroke. "My grandparents live alone in interior Latur and couldn't manage with the symptoms," said Ravi Shinde (name changed on request). He brought his grandmother to KEM Hospital in Parel for a consultation and was pleasantly surprised to hear a surgery-free method was possible. The device, a mitral clip, would help the valve close, prevent infections, and improve the quality of life. You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai "This was done within 15 days of our arrival in Mumbai," Shinde said, adding his grandmother was now breathing normally in the ward. The family only paid Rs 2,500 for registration. The 66-year-old patient suffered a heart attack a few months back and underwent angioplasty at a local hospital. "She initially improved but began experiencing breathlessness on exertion within a few months due to a leaking mitral valve—a known complication of heart attacks," said head of cardiology at KEM Hospital, Dr Ajay Mahajan, who performed the M-TEER (minimally invasive transcatheter edge-to-edge repair) on June 30. Tradionally, an open heart surgery was done to fix leaking valve, but now minimally invasive method is used. The patient was initially advised surgery, but it was risky due to her age and comorbidities. In the minimally invasive method, a clip-like device was inserted via a catheter, avoiding the need for surgery, Dr Mahajan explained. The KEM Hospital team got the made-in-India device for free as an inaugural offer by manufacturers Meril Life Sciences; the original American device costs around Rs 35 lakh. Senior cardiologist Dr Ashok Seth from Fortis Esco-rts Heart Institute in New Delhi, who conducted a clinical trial for the device, said it works well for those patients who can't withstand surgery.
India Today
24-06-2025
- Health
- India Today
Meril Launches MyClip, India's First Transcatheter-Edge-to-Edge Repair (TEER) System for Treatment of Severe Mitral Regurgitation
Meril Life Sciences, a leading global med-tech company, marked a significant milestone with the launch of MyClip, India's first Transcatheter Edge-To-Edge Repair (TEER) system, on June 14. The landmark Structural Heart Innovation event, held at Meril Academy, Vapi (Gujarat) from June 13–15, brought together over 150 Indian interventional cardiologists along with cardiac imaging expert and international stalwarts, including Prof. Ottavio Alfieri ('Father of mitral valve repair'), Prof. Francesco Maisano, and Prof. Agricola, joining global pioneers in edge-to-edge mitral valve is currently the world's leading TAVI group following the success of Myval THV and first Indian company to introduce a TEER system, placing the country firmly on the map as an innovator in transcatheter heart valve therapies (with both replacement and repair technology platforms). MyClip introduction demonstrates India's growing capabilities in structural heart solutions and reflects Meril's commitment to accessible cutting-edge cardiac TEER System is designed for patients suffering from severe Mitral Regurgitation (MR) who are at high surgical risk due to pre-existing issues like hypertension, diabetes, obesity, advanced age, physical frailty, enlarged or weak heart, and patients with kidney, lung and liver problems. MR, particularly if untreated, has a devastating mortality rate—over 50% of patients may not survive without timely intervention, and 1-year mortality can be as high as 57%.The MyClip TEER System enables precise closure of the mitral valve flaps, effectively preventing the backward flow of purified blood into the lungs. The procedure is minimally invasive, & takes approximately one hour, and allows patients to return home within 3–5 days. After discharge, patients can resume daily activities like walking and non-strenuous work within a short period post the to the landmark COAPT Study published in the New England Journal of Medicine (NEJM), patients receiving device-based therapy for mitral regurgitation experienced significantly better outcomes compared to those receiving standard medical treatment. Within 24 months, the hospitalization rate for heart failure was reduced to 35.8% per patient-year in the device group, compared to 67.9% in the control group. Additionally, mortality within the same period was notably lower in the device group, at 29.1%, compared to 46.1% in the control approximately 150 TEER (Transcatheter Edge-to-Edge Repair) procedures are performed annually in India, with the majority of patients falling in the younger age group (30 – 60). These statistics bring to light a pressing need for early and effective intervention in younger launch of MyClip TEER System marks a transformative moment for structural heart therapy in India. Transcatheter Edge-to-Edge Repair (TEER) therapy has shown significant success over traditional Guideline Directed Medical Therapy (GDMT). MyClip represents a major step forward in India's cardiovascular treatment landscape. In his inaugural speech, Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, said, 'In India, around 1.5 million people are known to have severe mitral regurgitation. Of these at least 1.2 million are post myocardial infarction (MI or a heart attack) or due to heart failure. Introduction of the MyClip TEER system marks a pivotal shift and we're witnessing early adoption. Meril's efforts in training cardiologists and building TEE-based imaging expertise are crucial steps in scaling this life-saving therapy across the country."'With MyClip, Meril is reshaping the country's role in global medtech. This homegrown innovation is a testament to what Indian science, engineering, and clinical collaboration can achieve together. Meril's nationwide public awareness campaign #TreatmentZarooriHai is in full swing, with brand ambassador MS Dhoni, to educate patients and families about the life-saving value of timely intervention in mitral valve regurgitation,' Mr. Bhatt two-day Structural Heart Innovation scientific program featured case demonstrations, interactive hands-on workshops, and the presentations leading Interventional Cardiologists and Echocardiologists. The event concluded with a call to build a sustainable M-TEER ecosystem in India, focused on accessibility, clinical excellence, and continuous The material and information contained are for advertorial purposes only. India Today holds no responsibility for the content written on the website as a basis for making any business, legal, or any other decision. Any reliance placed on such material is at your own risk.- Ends advertisement
Time of India
24-06-2025
- Health
- Time of India
Meril Launches MyClip, India's First Transcatheter-Edge-to-Edge Repair (TEER) System for treatment of Severe Mitral Regurgitation
Meril Life Sciences , a leading global med-tech company, marked a significant milestone with the launch of MyClip , India's first Transcatheter Edge-To-Edge Repair (TEER) system, on June 14. The landmark Structural Heart Innovation event, held at Meril Academy, Vapi (Gujarat) from June 13–15, brought together over 150 Indian interventional cardiologists along with cardiac imaging expert and international stalwarts, including Prof. Ottavio Alfieri ('Father of mitral valve repair '), Prof. Francesco Maisano, and Prof. Agricola, joining global pioneers in edge-to-edge mitral valve repair. Meril is currently the world's leading TAVI group following the success of Myval THV and first Indian company to introduce a TEER system, placing the country firmly on the map as an innovator in transcatheter heart valve therapies (with both replacement and repair technology platforms). MyClip introduction demonstrates India's growing capabilities in structural heart solutions and reflects Meril's commitment to accessible cutting-edge cardiac care . MyClip TEER System is designed for patients suffering from severe Mitral Regurgitation (MR) who are at high surgical risk due to pre-existing issues like hypertension, diabetes, obesity, advanced age, physical frailty, enlarged or weak heart, and patients with kidney, lung and liver problems. MR, particularly if untreated, has a devastating mortality rate—over 50% of patients may not survive without timely intervention, and 1-year mortality can be as high as 57%. The MyClip TEER System enables precise closure of the mitral valve flaps, effectively preventing the backward flow of purified blood into the lungs. The procedure is minimally invasive, & takes approximately one hour, and allows patients to return home within 3–5 days. After discharge, patients can resume daily activities like walking and non-strenuous work within a short period post the procedure. According to the landmark COAPT Study published in the New England Journal of Medicine (NEJM), patients receiving device-based therapy for mitral regurgitation experienced significantly better outcomes compared to those receiving standard medical treatment. Within 24 months, the hospitalization rate for heart failure was reduced to 35.8% per patient-year in the device group, compared to 67.9% in the control group. Additionally, mortality within the same period was notably lower in the device group, at 29.1%, compared to 46.1% in the control group. Currently, approximately 150 TEER (Transcatheter Edge-to-Edge Repair) procedures are performed annually in India, with the majority of patients falling in the younger age group (30 – 60). These statistics bring to light a pressing need for early and effective intervention in younger demographics. The launch of MyClip TEER System marks a transformative moment for structural heart therapy in India. Transcatheter Edge-to-Edge Repair (TEER) therapy has shown significant success over traditional Guideline Directed Medical Therapy (GDMT). MyClip represents a major step forward in India's cardiovascular treatment landscape. In his inaugural speech, Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, said, 'In India, around 1.5 million people are known to have severe mitral regurgitation. Of these at least 1.2 million are post myocardial infarction (MI or a heart attack) or due to heart failure. Introduction of the MyClip TEER system marks a pivotal shift and we're witnessing early adoption. Meril's efforts in training cardiologists and building TEE-based imaging expertise are crucial steps in scaling this life-saving therapy across the country." 'With MyClip, Meril is reshaping the country's role in global medtech. This homegrown innovation is a testament to what Indian science, engineering, and clinical collaboration can achieve together. Meril's nationwide public awareness campaign #TreatmentZarooriHai is in full swing, with brand ambassador MS Dhoni, to educate patients and families about the life-saving value of timely intervention in mitral valve regurgitation,' Mr. Bhatt added. The two-day Structural Heart Innovation scientific program featured case demonstrations, interactive hands-on workshops, and the presentations leading Interventional Cardiologists and Echocardiologists. The event concluded with a call to build a sustainable M-TEER ecosystem in India, focused on accessibility, clinical excellence, and continuous innovation. Disclaimer - The above content is non-editorial, and ET Healthworld hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.
Mint
23-06-2025
- Health
- Mint
Meril Launches MyClip, Transcatheter-Edge-to-Edge Repair (TEER) System in India
Meril Life Sciences, a global med-tech company, launched MyClip, a Transcatheter Edge-To-Edge Repair (TEER) system, on June 14. The Structural Heart Innovation event, held at Meril Academy, Vapi, Gujarat, from June 13–15, 2025, gathered over 150 Indian interventional cardiologists,cardiac imaging experts and international figures such as Prof. Ottavio Alfieri, Prof. Francesco Maisano, and Prof. Agricola. The introduction to MyClip indicates developments in structural heart solutions in India and reflects Meril's commitment to accessible cutting-edge cardiac care. MyClip TEER System is designed for patients with severe Mitral Regurgitation (MR) who face high surgical risk due to conditions such as hypertension, diabetes, obesity, advanced age, physical frailty, enlarged or weak heart, and patients with kidney, lung and liver problems. Untreated MR can have a significant mortality rate, with over 50% of patients not surviving without timely intervention, and a one-year mortality rate that can reach 57%. The MyClip TEER System allows for the precise closure of the mitral valve flaps, which can help prevent the backward flow of purified blood into the lungs. The procedure is minimally invasive, typically lasts about an hour, and may allow patients to return home within 3–5 days. Following discharge, patients may resume daily activities like walking and non-strenuous work relatively soon after the procedure. The COAPT Study, published in the New England Journal of Medicine (NEJM), reported that patients who received device-based therapy for mitral regurgitation experienced significantly better outcomes compared to those receiving standard medical treatment. Within 24 months, the hospitalisation rate for heart failure was reduced to 35.8% per patient-year in the device group, compared to 67.9% in the control group. Additionally, mortality within the same period was notably lower in the device group, at 29.1%, compared to 46.1% in the control group. Currently, approximately 150 TEERprocedures are performed annually in India, with the majority of patients falling in the age group of 30 to 60 years. These statistics bring to light a pressing need for early and effective intervention in younger demographics. In his inaugural speech, Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, said, 'In India, around 1.5 million people are known to have severe mitral regurgitation. Of these at least 1.2 million are post myocardial infarction (MI or a heart attack) or due to heart failure. Introduction of the MyClip TEER system marks a pivotal shift and we're witnessing early adoption. Meril's efforts in training cardiologists and building TEE-based imaging expertise are crucial steps in scaling this life-saving therapy across the country." 'With MyClip, Meril is reshaping the country's role in global medtech. This homegrown innovation is a testament to what Indian science, engineering, and clinical collaboration can achieve together. Meril's nationwide public awareness campaign #TreatmentZarooriHai with brand ambassador MS Dhoni aims to educate patients and families about the life-saving value of timely intervention in mitral valve regurgitation,' Mr. Bhatt added. The two-day Structural Heart Innovation scientific program featured case demonstrations, interactive hands-on workshops, and presentations by leading Interventional Cardiologists and Echocardiologists. The event concluded with a call to build a sustainable M-TEER ecosystem in India, focused on accessibility, clinical excellence, and continuous innovation.
Hans India
21-06-2025
- Health
- Hans India
Meril Launches MyClip, India's First Transcatheter-Edge-to-Edge Repair (TEER) System for Treatment of Severe Mitral Regurgitation
Meril Life Sciences, a leading global med-tech company, marked a significant milestone with the launch of MyClip, India's first Transcatheter Edge-To-Edge Repair (TEER) system, on June 14. The landmark Structural Heart Innovation event, held at Meril Academy, Vapi (Gujarat) from June 13–15, brought together over 150 Indian interventional cardiologists along with cardiac imaging expert and international stalwarts, including Prof. Ottavio Alfieri ('Father of mitral valve repair'), Prof. Francesco Maisano, and Prof. Agricola, joining global pioneers in edge-to-edge mitral valve repair. Meril is currently the world's leading TAVI group following the success of Myval THV and first Indian company to introduce a TEER system, placing the country firmly on the map as an innovator in transcatheter heart valve therapies (with both replacement and repair technology platforms). MyClip introduction demonstrates India's growing capabilities in structural heart solutions and reflects Meril's commitment to accessible cutting-edge cardiac care. MyClip TEER System is designed for patients suffering from severe Mitral Regurgitation (MR) who are at high surgical risk due to pre-existing issues like hypertension, diabetes, obesity, advanced age, physical frailty, enlarged or weak heart, and patients with kidney, lung and liver problems. MR, particularly if untreated, has a devastating mortality rate—over 50% of patients may not survive without timely intervention, and 1-year mortality can be as high as 57%. The MyClip TEER System enables precise closure of the mitral valve flaps, effectively preventing the backward flow of purified blood into the lungs. The procedure is minimally invasive, & takes approximately one hour, and allows patients to return home within 3–5 days. After discharge, patients can resume daily activities like walking and non-strenuous work within a short period post the procedure. According to the landmark COAPT Study published in the New England Journal of Medicine (NEJM), patients receiving device-based therapy for mitral regurgitation experienced significantly better outcomes compared to those receiving standard medical treatment. Within 24 months, the hospitalization rate for heart failure was reduced to 35.8% per patient-year in the device group, compared to 67.9% in the control group. Additionally, mortality within the same period was notably lower in the device group, at 29.1%, compared to 46.1% in the control group. Currently, approximately 150 TEER (Transcatheter Edge-to-Edge Repair) procedures are performed annually in India, with the majority of patients falling in the younger age group (30 – 60). These statistics bring to light a pressing need for early and effective intervention in younger demographics. The launch of MyClip TEER System marks a transformative moment for structural heart therapy in India. Transcatheter Edge-to-Edge Repair (TEER) therapy has shown significant success over traditional Guideline Directed Medical Therapy (GDMT). MyClip represents a major step forward in India's cardiovascular treatment landscape. In his inaugural speech, Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, said, 'In India, around 1.5 million people are known to have severe mitral regurgitation. Of these at least 1.2 million are post myocardial infarction (MI or a heart attack) or due to heart failure. Introduction of the MyClip TEER system marks a pivotal shift and we're witnessing early adoption. Meril's efforts in training cardiologists and building TEE-based imaging expertise are crucial steps in scaling this life-saving therapy across the country." 'With MyClip, Meril is reshaping the country's role in global medtech. This homegrown innovation is a testament to what Indian science, engineering, and clinical collaboration can achieve together. Meril's nationwide public awareness campaign #TreatmentZarooriHai is in full swing, with brand ambassador MS Dhoni, to educate patients and families about the life-saving value of timely intervention in mitral valve regurgitation,' Bhatt added. The two-day Structural Heart Innovation scientific program featured case demonstrations, interactive hands-on workshops, and the presentations leading Interventional Cardiologists and Echocardiologists. The event concluded with a call to build a sustainable M-TEER ecosystem in India, focused on accessibility, clinical excellence, and continuous innovation.
